"Immunization, Passive" - Books

Result Filters

Results: 1 to 20 of 309 books (1091 items)

<< First< Prev

Page of 16

Next >Last >>

Select item 49075341.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1c.)

Top results in this book Table of Contents

Select item 48845142.

Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1d.)

Top results in this book Table of Contents

Select item 48848123.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation Report [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1e.)

Top results in this book Table of Contents

Select item 48849384.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Health Technology Assessment Introduction and Clinical Review Protocol [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. (CADTH Optimal Use Report, No. 9.1a.)

Top results in this book Table of Contents

Select item 47615565.

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Clinical Section [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug. (CADTH Optimal Use Report, No. 8.3a.)

Top results in this book Table of Contents

Select item 32878926.

Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality.

Institute of Medicine (US) Vaccine Safety Committee; Stratton KR, Howe CJ, Johnston RB Jr, editors.

Washington (DC): National Academies Press (US); 1994.

Top results in this book Table of Contents

Select item 47617947.

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Implementation and Ethics Section [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep. (CADTH Optimal Use Report, No. 8.3b.)

Top results in this book Table of Contents

Select item 30760208.

Adverse Effects of Vaccines: Evidence and Causality.

Committee to Review Adverse Effects of Vaccines; Institute of Medicine; Stratton K, Ford A, Rusch E, et al., editors.

Washington (DC): National Academies Press (US); 2011 Aug 25.

Top results in this book Table of Contents

Select item 44036689.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2025 Jan-.

Top results in this book Table of Contents

Select item 488464010.

Axicabtagene Ciloleucel for Large B-cell Lymphoma: Implementation and Ethics Project Protocol [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. (CADTH Optimal Use Report, No. 9.1b.)

Top results in this book Table of Contents

Select item 488500011.

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Aug. (CADTH Optimal Use Report, No. 9.1f.)

Top results in this book Table of Contents

Select item 158168612.

Medical Microbiology. 4th edition.

Baron S, editor.

Galveston (TX): University of Texas Medical Branch at Galveston; 1996.

Top results in this book Table of Contents

Select item 195791613.

New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions.

National Research Council (US) and Institute of Medicine (US) Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction; Harwood HJ, Myers TG, editors.

Washington (DC): National Academies Press (US); 2004.

Top results in this book Table of Contents

Select item 141528014.

Madame Curie Bioscience Database [Internet].

Austin (TX): Landes Bioscience; 2000-2013.

Top results in this book Table of Contents

Select item 319327615.

The Anthrax Vaccine: Is It Safe? Does It Work?

Institute of Medicine (US) Committee to Assess the Safety and Efficacy of the Anthrax Vaccine; Joellenbeck LM, Zwanziger LL, Durch JS, et al., editors.

Washington (DC): National Academies Press (US); 2002.

Top results in this book Table of Contents

Select item 236397416.

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.

Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors.

Cambridge: Cambridge University Press; 2007.

Top results in this book Table of Contents

Select item 540176817.

Streptococcus pyogenes: Basic Biology to Clinical Manifestations [Internet]. 2nd edition.

Ferretti JJ, Stevens DL, Fischetti VA, editors.

Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2022 Oct 8.

Top results in this book Table of Contents

Select item 265918218.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Top results in this book Table of Contents

Select item 325078819.

Emerging Technologies for Nutrition Research: Potential for Assessing Military Performance Capability.

Institute of Medicine (US) Committee on Military Nutrition Research; Carlson-Newberry SJ, Costello RB, editors.

Washington (DC): National Academies Press (US); 1997.

Top results in this book Table of Contents

Select item 420372020.

Streptococcus pyogenes : Basic Biology to Clinical Manifestations [Internet].

Ferretti JJ, Stevens DL, Fischetti VA, editors.

Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016-.

Top results in this book Table of Contents

<< First< Prev

Page of 16

Next >Last >>

Supplemental Content

Images search in Bookshelf

Figure 1Proposed targets of anti-amyloid-β (Aβ) drugs used in active and passive immunization approaches (modified from (2)).

Immunotherapy Targeting Amyloid-β Peptides in Alzheimer’s Disease.

Huang X, editor. Alzheimer’s Disease: Drug Discovery [Internet]. Brisbane (AU): Exon Publications; 2020 Dec 18.
Figure A.41Immunity can be transferred by antibodies or by lymphocytes

Successful vaccination leads to a long-lived state of protection against the specific immunizing pathogen. If this immune protection can be transferred to a normal syngeneic recipient with serum from an immune donor, then immunity is mediated by antibodies; such immunity is called humoral immunity and the process is called passive immunization. If immunity can only be transferred by infusing lymphoid cells from the immune donor into a normal syngeneic recipient, then the immunity is called cell-mediated immunity and the transfer process is called adoptive transfer or adoptive immunization. Passive immunity is short-lived, as antibody is eventually catabolized, but adoptively transferred immunity is mediated by immune cells, which can survive and provide longer-lasting immunity.

Appendix I. Immunologists' Toolbox.

Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001.
FIGURE A-5

Immunization effects on cocaine self-administration in rats. Rats were trained to self-administer intravenous doses of cocaine by pressing a lever. The top line (control) shows the number of lever presses each day in control rats. One group had saline substituted for cocaine, resulting in decreased lever pressing. A third group continued to have access to cocaine but received an injection of cocaine-specific monoclonal antibodies. Lever pressing in this group decreased to the same extent as the saline substitution group. This experiment illustrates the use of passive immunization. A similar decrease in lever pressing can be obtained with vaccination but requires 6 weeks to become evident because of the gradual rise in antibody levels in vaccinated rats.
SOURCE: Adapted from Fox et al. (1996).

Vaccines and Depot Medications for Drug Addiction: Rationale, Mechanisms of Action, and Treatment Implications.

National Research Council (US) and Institute of Medicine (US) Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction; Harwood HJ, Myers TG, editors. New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington (DC): National Academies Press (US); 2004.
FIGURE A-6

Passive immunization produces long-lasting attenuation of the locomotor activating effects of phencyclidine. Rats received a single intravenous dose of phencyclidine-specific monoclonal IgG (the most common class of antibody) and were challenged with a phencyclidine injection at various times afterward. The top five lines represent control animals, which received saline treatment, showing locomotor activation at all phencyclidine doses. The bottom five lines represent immunized animals that received phencyclidine-specific IgG. Locomotor activity after each phencyclidine challenge dose was attenuated, even 2 weeks after the antibody was administered. *p <.05.
SOURCE: Adapted from Hardin et al. (2002).

Vaccines and Depot Medications for Drug Addiction: Rationale, Mechanisms of Action, and Treatment Implications.

National Research Council (US) and Institute of Medicine (US) Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction; Harwood HJ, Myers TG, editors. New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington (DC): National Academies Press (US); 2004.